Avalo Therapeutics, Inc. develops therapies for immune-mediated inflammatory diseases by targeting the IL-1β pathway, which plays a key role in inflammation. Its lead product, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody being investigated for hidradenitis suppurativa and other immune-mediated conditions. The company is also advancing AVTX-010, a long-acting anti-IL-1β monoclonal antibody designed to extend dosing intervals. Avalo focuses on addressing significant unmet clinical needs in various global markets.
- Website
- www.avalotx.com
- Issuer profile
- All listings